Following the creation of the company by TIAP and adMare BioInnovations, the technology was developed through preclinical proof of concept by Zucara and is now in clinical development. These activities were supported by over US$5M in funding from organizations such as Breakthrough T1D (formerly JDRF), The Helmsley Charitable Trust, Mitacs, GlycoNet, and NRC-IRAP. The funding allowed Zucara to define its lead drug candidate, ZT-01 and complete IND/CTA enabling activities. In 2020, Zucara completed a US$21M Series A financing led by the Perceptive Xontogeny Venture Fund enabling several Phase 1 studies, including a positive proof-of-concept study. In 2024, Zucara raised US$20M in a Series B financing with existing investor, the Perceptive Xontogeny Venture Fund and strategic investor, Sanofi to complete Zucara’s ongoing Phase 2a trial of the effect of ZT-01 On Nocturnal hypoglycemia Events in Type 1 diabetes (“T1D”) mellitus (“ZONE”), and nonclinical activities to support a once-weekly version of ZT-01.